Literature DB >> 11846943

Coadministration of methylprednisolone with hypertonic saline solution improves overall neurological function and survival rates in a chronic model of spinal cord injury.

J J Legos1, K R Gritman, R F Tuma, W F Young.   

Abstract

OBJECTIVE: We previously demonstrated that administration of 7.5% hypertonic saline (HS) significantly improved spinal cord blood flow and neurological outcomes after spinal cord injury. The aim of this study was to determine whether hypertonicity would enhance the effects of methylprednisolone (MP), further improving neurological function.
METHODS: Rat spinal cords were compressed for 10 minutes with 50 g of weight, and neurological function was assessed for 28 days, using the Basso-Beattie-Bresnahan locomotor rating scale. The control group received an intravenous injection of isotonic saline (IS) (5 ml/kg). Group 1 received an intravenous injection of 7.5% HS (5 ml/kg). Group 2 received an intravenous injection of MP (30 mg/kg) and IS (5 ml/kg). Group 3 received an intravenous injection of MP (30 mg/kg) administered with 7.5% HS (5 ml/kg).
RESULTS: At 24 hours after spinal cord injury, the combination of MP plus HS provided significant (P < 0.01) neurological improvements, compared with all other treatment groups. At 10 days after injury, the animals that had received MP plus HS exhibited significantly (P < 0.01) higher Basso-Beattie-Bresnahan scores, compared with the MP plus IS and control groups. The median survival time was significantly (P < 0.01) increased for the MP plus HS group (28 d), compared with the MP plus IS group (16 d). Because of the dramatic decrease in survival rates at 28 days after injury, there was a significant (P < 0.01) difference in neurological function only between the MP plus HS group and the control group.
CONCLUSION: The results indicate that the administration of HS may enhance the delivery of MP and prevent immunosuppression, leading to improvements in overall neurological function and survival rates after spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11846943     DOI: 10.1097/00006123-200112000-00022

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

Review 1.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

2.  Comparison of systemic and localized carrier-mediated delivery of methylprednisolone succinate for treatment of acute spinal cord injury.

Authors:  Maxim E Baltin; Diana E Sabirova; Elvira I Kiseleva; Marat I Kamalov; Timur I Abdullin; Natalia V Petrova; Nafis F Ahmetov; Oscar A Sachenkov; Tatiana V Baltina; Igor A Lavrov
Journal:  Exp Brain Res       Date:  2021-01-02       Impact factor: 1.972

Review 3.  [Prehospital management of spinal cord injuries].

Authors:  M Bernhard; A Gries; P Kremer; A Martin-Villalba; B W Böttiger
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

Review 4.  Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Authors:  Young-tae Kim; Jon-Michael Caldwell; Ravi V Bellamkonda
Journal:  Biomaterials       Date:  2009-01-30       Impact factor: 12.479

5.  Hypertonic saline attenuates cord swelling and edema in experimental spinal cord injury: a study utilizing magnetic resonance imaging.

Authors:  Yvette S Nout; Georgeta Mihai; C Amy Tovar; Petra Schmalbrock; Jacqueline C Bresnahan; Michael S Beattie
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

6.  Aquaporin 1 - a novel player in spinal cord injury.

Authors:  O Nesic; J Lee; G C Unabia; K Johnson; Z Ye; L Vergara; C E Hulsebosch; J R Perez-Polo
Journal:  J Neurochem       Date:  2008-01-28       Impact factor: 5.372

7.  Administration of High-Dose Methylprednisolone Worsens Bone Loss after Acute Spinal Cord Injury in Rats.

Authors:  Yuanzhen Peng; Wei Zhao; Yizhong Hu; X Edward Guo; Jun Wang; Ke Hao; Zhiming He; Carlos Toro; William A Bauman; Weiping Qin
Journal:  Neurotrauma Rep       Date:  2021-12-08

Review 8.  Elevated intraspinal pressure in traumatic spinal cord injury is a promising therapeutic target.

Authors:  Chao-Hua Yang; Zheng-Xue Quan; Gao-Ju Wang; Tao He; Zhi-Yu Chen; Qiao-Chu Li; Jin Yang; Qing Wang
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

9.  Anterior chamber associated immune deviation used as a neuroprotective strategy in rats with spinal cord injury.

Authors:  Beatriz Pineda-Rodriguez; Diana Toscano-Tejeida; Elisa García-Vences; Roxana Rodriguez-Barrera; Adrian Flores-Romero; Daniela Castellanos-Canales; Gabriel Gutierrez-Ospina; Laura Castillo-Carvajal; Esperanza Meléndez-Herrera; Antonio Ibarra
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

10.  Valproic acid-labeled chitosan nanoparticles promote recovery of neuronal injury after spinal cord injury.

Authors:  Dimin Wang; Kai Wang; Zhenlei Liu; Zonglin Wang; Hao Wu
Journal:  Aging (Albany NY)       Date:  2020-05-28       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.